B cell

Ashlee Morgan Scholarship for Healthcare Students: Nurturing Passion and Innovation in Healthcare Education

Retrieved on: 
Thursday, February 29, 2024
Interest, Medicine, Knowledge, B cell, Amnion, Science, Regenerative medicine, Patient, Student, Nursing

This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.

Key Points: 
  • This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.
  • To be eligible for the Ashlee Morgan Scholarship for Healthcare Students, applicants must be current undergraduate or graduate students pursuing a degree in a healthcare-related field.
  • The Ashlee Morgan Scholarship for Healthcare Students represents a commitment to nurturing the future leaders and innovators in healthcare.
  • By recognizing excellence, passion, and innovation, Ashlee Morgan aims to contribute to the evolution of medicine and improve lives.

HPV's Hidden Hand: New Study by Pusan National University Scientists Reveals Key Details in Head and Neck Cancer Microenvironment

Retrieved on: 
Wednesday, February 28, 2024
School, Neoplasm, Incidence, PKM2, Viral, Virology, Informatics, Assistant, Throat, Growth, Health informatics, Human papillomavirus infection, Branches of microbiology, Mouth, RNA, PKM, Tumor microenvironment, B cell, Ephrin, Patient, Glomus tumor, Journal, Tobacco, Medicine, Pusan National University, HPV, HNSCC, Head, Research, Nose, Cancer, EPHA2, Vaccine

BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.

Key Points: 
  • BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat.
  • The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.
  • Therefore, the HPV infection could be considered a criterion for developing treatment strategies, thereby enabling precision medicine tailored to the patient's condition!
  • Title of original paper: Deciphering Head and Neck Cancer Microenvironment: Single–Cell and Spatial Transcriptomics Reveals Human Papillomavirus–Associated Differences

Unlocking the Secrets to Longevity: Live Beyond the Norms - A Global Online Summit Featuring Leading Health Experts

Retrieved on: 
Wednesday, February 21, 2024
Online, Secrecy, Multimedia, Diet, Ageing, Life, B cell, Health, Genetic testing, FREE, Research

The summit aims to address the growing shift in the research and medical communities towards understanding longevity.

Key Points: 
  • The summit aims to address the growing shift in the research and medical communities towards understanding longevity.
  • But why live longer if you don't have health, vitality, and a youthful mindset?
  • Ben Greenfield, offering a blueprint to a healthier life and unlocking key pillars for health and longevity.
  • To register for Uncovering the Secrets to Longevity: Live Beyond the Norms and access these transformative insights, visit https://secretstolongevity.byhealthmeans.com/?idev_id=33732 .

Pusan National University Researchers Reveal How Diabetes Weakens Gum Defense

Retrieved on: 
Friday, February 16, 2024
Diabetes, PD, Translation, Assistant, Type, Blood, Inflammation, South Korea, Cell, Risk, RNA, Cytokine, B cell, Clinical, Patient, NK, Monocyte, Insulin resistance, Pusan National University, Periodontal disease, Research, Vaccine

BUSAN, South Korea, Feb. 16, 2024 /PRNewswire/ -- Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM). Despite the profound implications for overall health, the complex bidirectional relationship between them lacks a comprehensive understanding so far, leaving the precise nature of their immunological connection inadequately understood. Prior studies focusing on local immune responses in gingival tissue fall short in capturing the systemic immunological relationship.

Key Points: 
  • BUSAN, South Korea, Feb. 16, 2024 /PRNewswire/ -- Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM).
  • In an innovative study, researchers from the Republic of Korea have investigated the relationship between periodontitis (PD) and diabetes mellitus (DM).
  • Led by Assistant Professor Yun Hak Kim from Pusan National University, the study employs pioneering single-cell RNA analysis and digs into the immune dynamics at the cellular level.
  • In conclusion, this groundbreaking research provides a first-of-its-kind immunological explanation for the complex association between periodontitis and type 2 diabetes mellitus.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia and HIV Published in The New England Journal of Medicine (NEJM)

Retrieved on: 
Wednesday, February 14, 2024
Oncology, AIDS, Health, Infectious Diseases, Hospitals, Research, Science, Infection, Bone marrow, Cancer, Division, Immune system, Multimedia, Syndrome, Graft-versus-host disease, Acute leukemia, Blood, CCR5, Haematopoietic system, Transplant, Government, BMT, National Cancer Institute, Laboratory, B cell, Gene therapy, Medicare, Patient, Mutation, HIV, Dentistry

View the full release here: https://www.businesswire.com/news/home/20240214747351/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214747351/en/
    "City of Hope Patient" Paul Edmonds with City of Hope doctors, Jana K. Dickter, M.D., and Monzr Al Malki, M.D.
  • Edmonds is also the person who had HIV the longest — for over 31 years — among these five patients.
  • Known as the “City of Hope patient” among these five patients, Edmonds received a transplant at City of Hope on Feb. 6, 2019, and is now considered to be cured of leukemia.
  • City of Hope has exceptional transplant outcomes year after year, according to the Center for International Blood & Marrow Transplant Research.

ELREXFIO™ is authorized by Health Canada for adults with relapsed or refractory multiple myeloma in Canada

Retrieved on: 
Tuesday, February 13, 2024
Bone marrow, Health Canada, Multiple myeloma, RRMM, News, Pfizer, B cell, Myeloma Canada, Patient, Disease, Cancer, Pharmaceutical industry

KIRKLAND, QC, Feb. 13, 2024 /CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection).

Key Points: 
  • KIRKLAND, QC, Feb. 13, 2024 /CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection).
  • "The approval of ELREXFIO is good news for patients and their healthcare teams as it offers a new treatment possibility for those living with the disease."
  • Multiple myeloma is the second-most common type of blood cancer, with an estimated 11 Canadians being diagnosed with myeloma every day.iii It is estimated that in 2023, 3,900 Canadians were diagnosed with multiple myeloma and 1,700 Canadians died from the disease.iv
    "Multiple myeloma can be an incredibly challenging cancer to live with and manage," said Martine Elias, Executive Director at Myeloma Canada.
  • This is why it's so important that people living with the disease have access to many and new options even more so when they have relapsed."

Parent Project Muscular Dystrophy Provides $500,000 in Funding to Kinea Bio Through PPMD Venture Pathways Program to Support Next-Gen Midi-Dystrophin Gene Therapy Development

Retrieved on: 
Tuesday, February 13, 2024
Gene, Doctor of Philosophy, Genetic disorder, Quality of life, DMD, Duchenne muscular dystrophy, Risk, Health, Protein, Patient, Knowledge, B cell, Male, PPMD, AAV, Vaccine

WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.

Key Points: 
  • WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.
  • The organization prioritizes research for next-generation and future-generation gene therapies both through PPMD's Gene Therapy Initiative and the PPMD Venture Pathways program.
  • Casey Childers, DO, PhD, Chief Executive Officer of Kinea Bio, explains:
    "We are pleased to receive this funding commitment from PPMD.
  • In addition to PPMD's significant pre-clinical and academic research funding, the organization provides funding to biopharmaceutical companies through PPMD Venture Pathways, its venture philanthropy program.

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
Monday, February 12, 2024
Nitrogen oxide, Conference call, Nitric oxide, Research, PMA, B cell, Hebrew University of Jerusalem, FDA, Clinical research associate, SITC, NOS1, UNO, Pneumonia, Season, ASD, Society, Conference, Commercial, HUJI, Phenotype, Patient, DSM-IV codes, Immunotherapy, VCAP, NTM, Fiscal year, Nontuberculous mycobacteria

“In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.

Key Points: 
  • “In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.
  • This increasing demand for our current LungFit PH system was seen even as we prepared to launch a key software update.
  • As our inventory of upgraded LungFit PH grows, we expect to be able to meet accelerating demand over the next several quarters.
  • General and administrative expenses for the three months ended December 31, 2023 and December 31, 2022 were $9.8 million and $8.9 million, respectively.